USPTO awards patent to Sanovas' Abrading Balloon Catheter for Extravasated Drug Delivery

Sanovas, Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies announced today that the United States Patent and Trademark Office issued patent # 8,597,239 for the company's Abrading Balloon Catheter for Extravasated Drug Delivery.

The Abrading Balloon Catheter for Extravasated Drug Delivery is a multi-lumen balloon catheter that features abrasive outer surfaces upon the substrate of the balloons that are intended to abrade tissue and stimulate cellular function to optimize the osmotic uptake of therapeutic agents into target tissues. The device temporarily occludes a specific region to create a localized treatment chamber for the focal and/or circumferential delivery of various types of therapeutic agents to treat a variety of disease states via the company's patented methods of extravasated drug delivery.

"We believe clinicians will appreciate the broad utility of this asset," related Sanovas CEO, Larry Gerrans. "This will be an intelligent and effective device intended to significantly improve localized, precision therapies. It is analogous to the Swiss Army Knife of Drug Delivery Catheters."

The technology measures and modulates the volumetric pressure gradients of therapeutic agent(s) within the treatment chamber(s) to perfuse the agent(s) across the tissue membrane enabling controlled delivery of the agents directly to target tissues. The system affords clinicians substantial procedural control, including the ability to select the therapeutic agent(s) of their choice and to continuously circulate, irrigate, abrade, extravasate and evacuate the treatment site while mitigating the systemic release of the agent.

"This patent is a significant cornerstone to the company's NanoVas™ portfolio of Interventional Drug Delivery Solutions," said Gerrans. "These tools are vital to the continued growth and promise of Personalized Medicine."  

Sanovas expects to commercialize the technology in coordination with its various partners to meet unmet clinical needs in Pulmonology, Cardiology, Neurology and Uro-Gynecology.